Gritstone bio, Inc. (GRTS)
Market Cap | 145.87M |
Revenue (ttm) | 10.23M |
Net Income (ttm) | -138.96M |
Shares Out | 95.34M |
EPS (ttm) | -1.24 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,782,906 |
Open | 1.32 |
Previous Close | 1.30 |
Day's Range | 1.28 - 1.55 |
52-Week Range | 1.14 - 4.05 |
Beta | 0.63 |
Analysts | Strong Buy |
Price Target | 7.33 (+379.09%) |
Earnings Date | Nov 8, 2023 |
About GRTS
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops ... [Read more]
Financial Performance
In 2022, Gritstone bio's revenue was $19.95 million, a decrease of -58.63% compared to the previous year's $48.21 million. Losses were -$119.69 million, 59.4% more than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for GRTS stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 379.09% from the latest price.
News

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

Presentations at IDWeek 2023 Highlight Potentially Differentiated Immunogenicity of Gritstone bio's Next Generation COVID-19 Vaccine
-- High neutralizing antibody (nAb) responses sustained through at least 12 months, highlighting potential for durable clinical protection -- -- T cell responses to Spike plus other viral targets obse...

Gritstone bio Announces Presentations from Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19 at IDWeek 2023
EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced re...

Gritstone bio wins $433 million US award for COVID vaccine study
Gritstone bio on Wednesday secured a $433 million contract by the U.S. government to conduct a mid-stage study of its self-amplifying mRNA COVID-19 vaccine candidate.

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million
Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433M

Gritstone bio to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced t...

Gritstone bio and Genevant Sciences Announce Option and License Agreement
Agreement provides nonexclusive access to Genevant's leading LNP technology for use with Gritstone bio's self-amplifying RNA technology in wide array of infectious disease vaccines

Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
-- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); prelimi...

Gritstone bio Partners with Friends of Cancer Research (Friends) on the ctDNA to Monitor Treatment Response (ctMoniTR) Project
EMERYVILLE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

Gritstone bio Announces Publication of Interim Results from Phase 1 Study of Self-amplifying mRNA (samRNA) Vaccine Against COVID-19 in Nature Communications
-- Potent and durable immunogenicity achieved with low dose self-amplifying mRNA vaccine (samRNA) candidate -- -- Immunity boosted for at least 6 months in previously vaccinated-older adults (administ...

Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023
EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it ...

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)
-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including variant cross-reactive nAb, in previously unvaccinat...

Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting
-- Longitudinal analysis of GRANITE recipients (personalized vaccine candidate now in Phase 2/3 for MSS-CRC) demonstrates vaccine-elicited priming and boosting of antigen-specific T cell populations a...

Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023
EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced m...

Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting
EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced m...

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals f...

Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference
EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced th...

Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
-- NCI will lead the Phase 1 study using Gritstone's proprietary “off the shelf” vaccine technology for mutant KRAS solid tumors -- -- NCI will lead the Phase 1 study using Gritstone's proprietary “of...

Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced th...

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)
-- Patents support Gritstone's pioneering work in the application of next-generation samRNA vaccine technology in oncology and infectious disease -- -- Patents support Gritstone's pioneering work in t...

Gritstone to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update
-- Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application of self-amplifying mRNA (samRNA) as infectious disease vaccine platform -- -- Initi...

Gritstone bio Announces Private Placement of $45.0 Million
EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases
-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination -- -- Interim results from CORAL-CE...